Long-term growth drivers
Alexion Pharmaceuticals (ALXN) is focused on developing effective drugs for rare diseases. In March 2017, the company filed a supplemental Biologics License Application (sBLA) for Soliris as a therapy for refractory gMG (generalized myasthenia gravis). If the drug receives approval for this indication, Alexion Pharmaceuticals’ might witness higher revenue.
Currently, Alexion Pharmaceuticals is carrying out the PREVENT phase 3 trial, which is evaluating Soliris as s treatment option for relapsing Neuromyelitis Optica Spectrum Disorder.
Alexion Pharmaceuticals also expects promising results for ALXN1210, a long-acting anti-C5 antibody, which is being studied in phase 3 clinical trials for PHN (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic-uremic syndrome). The approval of Soliris for NMOSD and ALXN1210 for PNH and aHUS would boost the company’s long-term revenue growth.
Alexion Pharmaceuticals’ other products in clinical trials include cPMP for Molybdenum Cofactor Deficiency type A and SBC-103 for Mucopolysaccharidoses IIIB.
For Alexion Pharmaceuticals, increased product sales might fuel the share prices of the Vanguard Growth ETF (VUG). Alexion Pharmaceuticals holds ~0.21% of VUG’s total portfolio holdings.
Of the 21 analysts analyzing Alexion Pharmaceuticals, six analysts recommended a “strong buy” and 11 analysts recommended a “buy.”
Four analysts recommended a “hold,” while ~80% of the analysts suggested some form of a “buy.”
Out of 26 analysts analyzing Biogen (BIIB) in May 2017, seven analysts recommended a “strong buy,” while eight analysts recommended a “buy.” Ten analysts recommended a “hold,” while one analyst recommended a “sell.” Meanwhile, ~58% of the analysts covering Biogen suggested some form of a “buy.”
Out of 21 analysts analyzing BioMarin Pharmaceutical (BMRN) in May 2017, six analysts recommended a “strong buy,” while ten analysts recommended a “buy.” Five analysts recommended a “hold,” while none of the analysts recommended a “strong sell” or “sell.” Meanwhile, ~76% of the analysts suggested some form of a “buy.”
Of the six analysts analyzing Syros Pharmaceuticals (SYRS) in May 2017, two analysts recommended a “strong buy,” while three analysts recommended a “buy.” One analyst recommended a “hold.” No analysts recommended a “sell” or “strong sell.” Meanwhile, ~83% of the analysts recommended some form of a “buy.”